Overview

• In matched cohorts of 6,070 statin users and 6,070 non-users drawn from the MIMIC-IV database, 28-day all-cause mortality was 14.3% with statins versus 23.4% without.
• The study employed propensity score matching to balance patient characteristics and reduce confounding in treatment allocation.
• Researchers point to statins’ anti-inflammatory, immunomodulatory, antioxidative and antithrombotic effects as potential mechanisms for improved survival.
• Survivors who received statins experienced slightly longer durations of mechanical ventilation and renal replacement therapy, suggesting extended recovery support.
• Investigators and sepsis specialists underline the urgent need for large, rigorously designed randomized trials to confirm these observational findings and establish causality.